- Sorrento Therapeutics Inc (NASDAQ:SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.
- Abivertinib selectively inhibits EGFR-activating and resistant mutation with nearly 300-fold greater potency than wild-type EGFR.
- In these Independent Review Committee (IRC)-assessed preliminary data, Abivertinib showed significant treatment benefits in 209 response evaluable, heavily treated NSCLC patients with an ORR of 56.5%.
- Related: Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer.
- A significant CR rate was seen with Abivertinib (5.3%) compared to AstraZeneca Plc’s (NASDAQ:AZN) Tagrisso (osimertinib) (0.5%), while the ORR rate is comparable between the two drugs.
- Overall survival was 28.2 months (versus Tagrisso’s median OS of 26.8 months).
- Sorrento is preparing the pre-FDA marketing application materials and package.
- Price Action: SRNE shares are up 5.51% at $1.87 on the last check Tuesday.
AI Boom Fuels Optimistic Outlook For Key Apple Supplier: IQE Sees Strong Order Book In 2024 Despite ‘Persisting Uncertainties In Global Economy’
The company produces "epi-wafers," a sophisticated material used in various products ranging from laser hair removal systems to facial recognition sensors found in Apple's iPhones.
